The US Food and Drug Administration (FDA) has increased its collaboration with cancer drug manufacturers in a bid to overcome the country’s ongoing drug shortage problem and reduce impacts on patients ...
An Israeli company that has a U.S. headquarters in Waltham said Monday it has received approval for a new drug for blood cancer. Biopharmaceutical company BioLineRx Ltd. (Nasdaq: BLRX) said the U ...
What do you do when the country you rely on for your life-saving medicines is the one you consider your systemic rival? Every day, many tons of chemicals are churned out in Chinese factories, which ...
Sept 15 (Reuters) - (This Sept. 15 story has been corrected show that momelotinib is approved for patients regardless of prior myelofibrosis therapy, not just for patients previously treated ...
Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Wednesday the U.S. Food and Drug Administration (FDA) ...
An Israeli company that has a U.S. headquarters in Waltham said Monday it has received approval for a new drug for blood cancer. Biopharmaceutical company BioLineRx Ltd. said the U.S. Food and ...
Cancer experts have made two calls for action from US lawmakers this year: fix the ongoing cancer drug shortage, and increase funding for cancer research. The American Association for Cancer ...
A Food and Drug Administration advisory panel on Tuesday unanimously concluded that oral phenylephrine, the decongestant found in many common cold medications, is ineffective. Phenylephrine is ...
FDA reduced the therapeutic equivalence rating for Accord Healthcare's tacrolimus oral capsules due to safety concerns. The generic is still approved and allowed to be prescribed.
Phenylephrine, a popular ingredient in many over-the-counter allergy and cold medicines, is ineffective in tablet form, an independent advisory committee to the US Food and Drug Administration ...
(Reuters) - (This Sept. 15 story has been corrected show that momelotinib is approved for patients regardless of prior myelofibrosis therapy, not just for patients previously treated with JAK ...
British drugmaker GSK Plc said on Friday the US Food and Drug Administration had approved its oral therapy to treat anemia in patients with a type of bone marrow cancer called myelofibrosis.
